- Home
- Molecular Point Of Care Testing Using Naat Market
Global Molecular Point of Care Testing (Using NAAT) Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-168 | No of pages: 424 | Format:
Global molecular point of care testing (using NAAT) market is projected to register a substantial CAGR of 10.8% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020, and the forecast period is 2021 to 2028.
Market Segmentation:
Global Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Region (North America, Global, South-Asia, South East Asia, Middle East, and Africa), Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the global dandruff treatment market are:
Introduction of innovative and technology products and rising disposable income
An increasing number of product launches
Market Players:
Some of the key market players for the global molecular point of care testing (using NAAT) market are listed below:
Danaher
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
Sekisui Diagnostics
QuantuMDx Group Ltd.
Lucira Health Inc.
binx health, inc.
Sysmex (A Subsidiary of Sysmex Corporation)
Co-Diagnostics, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.7 MULTIVARIATE MODELLING 54
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 54
2.9 DBMR MARKET POSITION GRID 55
2.10 VENDOR SHARE ANALYSIS 57
2.11 MARKET END USER COVERAGE GRID 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PORTERS FIVE FORCES 65
4.2 PESTEL ANALYSIS 66
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 67
4.3.1 CEPHEID 67
4.3.2 THERMO FISHER SCIENTIFIC INC. 68
4.3.3 HOLOGIC, INC. 69
4.3.4 BD 70
4.3.5 F. HOFFMANN-LA ROCHE LTD 71
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 72
4.5 PRICE PER POCT INSTRUMENT 73
4.5.1 NORTH AMERICA 73
4.5.2 EUROPE 75
4.5.3 SOUTH ASIA 76
4.5.4 SOUTH EAST ASIA 78
4.5.5 MIDDLE EAST 81
4.5.6 AFRICA 83
4.6 PRICE PER TEST 85
4.6.1 NORTH AMERICA 85
4.6.2 EUROPE 93
4.6.3 SOUTH ASIA 101
4.6.4 SOUTH EAST ASIA 109
4.6.5 MIDDLE EAST 121
4.6.6 AFRICA 133
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS 141
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) 145
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS 149
4.10 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS 152
4.11 DISTRIBUTORS 155
4.11.1 NORTH AMERICA 155
4.11.2 EUROPE 156
4.11.3 SOUTH ASIA 158
4.11.4 SOUTH EAST ASIA 159
4.11.5 MIDDLE EAST 161
4.11.6 AFRICA 162
5 REGULATORY FRAMEWORK 163
6 MARKET OVERVIEW 166
6.1 DRIVERS 168
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 168
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 168
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 169
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 169
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 170
6.2 RESTRAINTS 171
6.2.1 PRODUCT RECALLS 171
6.2.2 HIGH COSTS OF PRODUCTS 171
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 172
6.3 OPPORTUNITIES 172
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 172
6.3.2 RISING HEALTHCARE EXPENDITURE 173
6.3.3 PANDEMIC OUTBREAK OF COVID-19 174
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 174
6.4 CHALLENGES 175
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 175
6.4.2 LACK OF ACCESSIBILITY 175
7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 177
7.1 IMPACT ON PRICE 177
7.2 IMPACT ON DEMAND 177
7.3 IMPACT ON SUPPLY CHAIN 178
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 178
7.5 CONCLUSION: 179
8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 180
8.1 OVERVIEW 181
8.2 CONSUMABLES & REAGENTS 184
8.3 INSTRUMENTS 184
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 185
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 185
9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 186
9.1 OVERVIEW 187
9.2 RESPIRATORY INFECTIONS TESTING 190
9.2.1 COVID-19 191
9.2.2 FLU B 191
9.2.3 FLU A 191
9.2.4 RSV 191
9.2.5 TUBERCULOSIS 191
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 191
9.2.7 OTHERS 192
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 192
9.3.1 TV 193
9.3.2 CT 193
9.3.3 NG 193
9.3.4 HPV 193
9.3.5 HSV 193
9.3.6 MG 193
9.3.7 UU 194
9.3.8 MH 194
9.3.9 OTHERS 194
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 194
9.4.1 GROUP B STREPTOCOCCUS 195
9.4.2 SHIGA TOXIN 195
9.4.3 H. PYLORI 195
9.5 OTHERS 196
10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 197
10.1 OVERVIEW 198
10.2 LABORATORIES 201
10.3 HOSPITAL 201
10.4 CLINICS 202
10.5 AMBULATORY CENTER 203
10.6 HOMECARE 203
10.7 ASSISTED LIVING FACILITIES 204
10.8 OTHERS 205
11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 206
11.1 OVERVIEW 207
11.2 PRESCRIPTION-BASED TESTING 210
11.3 OTC TESTING 211
12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 212
12.1 OVERVIEW 213
12.2 DIRECT SALES 216
12.3 THIRD PARTY DISTRIBUTOR 216
12.4 ONLINE SALES 217
13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 218
13.1 OVERVIEW 219
13.2 NORTH AMERICA 224
13.2.1 U.S. 231
13.2.2 CANADA 235
13.3 EUROPE 239
13.3.1 U.K. 247
13.3.2 GERMANY 251
13.3.3 ITALY 255
13.3.4 FRANCE 259
13.3.5 SPAIN 263
13.3.6 REST OF EUROPE 267
13.4 SOUTH ASIA 268
13.4.1 INDIA 276
13.4.2 PAKISTAN 280
13.4.3 BANGLADESH 284
13.4.4 REST OF SOUTH ASIA 288
13.5 SOUTH EAST ASIA 289
13.5.1 SINGAPORE 297
13.5.2 VIETNAM 301
13.5.3 THAILAND 305
13.5.4 MALAYSIA 309
13.5.5 INDONESIA 312
13.5.6 PHILIPPINES 316
13.5.7 REST OF SOUTH EAST ASIA 320
13.6 MIDDLE EAST 321
13.6.1 SAUDI ARABIA 329
13.6.2 U.A.E 333
13.6.3 ISRAEL 337
13.6.4 EGYPT 341
13.6.5 REST OF MIDDLE EAST 345
13.7 AFRICA 346
13.7.1 SOUTH AFRICA 354
13.7.2 KENYA 358
13.7.3 NIGERIA 362
13.7.4 REST OF AFRICA 366
14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 367
14.1 COMPANY SHARE ANALYSIS: GLOBAL 367
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 368
14.3 COMPANY SHARE ANALYSIS: EUROPE 369
14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA 370
15 SWOT ANALYSIS 371
16 COMPANY PROFILE 372
16.1 DANAHER 372
16.1.1 COMPANY SNAPSHOT 372
16.1.2 REVENUE ANALYSIS 372
16.1.3 COMPANY SHARE ANALYSIS 373
16.1.4 PRODUCT PORTFOLIO 373
16.1.5 RECENT DEVELOPMENTS 374
16.2 THERMO FISHER SCIENTIFIC INC. 375
16.2.1 COMPANY SNAPSHOT 375
16.2.2 REVENUE ANALYSIS 375
16.2.3 COMPANY SHARE ANALYSIS 376
16.2.4 PRODUCT PORTFOLIO 376
16.2.5 RECENT DEVELOPMENTS 376
16.3 HOLOGIC, INC. 377
16.3.1 COMPANY SNAPSHOT 377
16.3.2 REVENUE ANALYSIS 377
16.3.3 COMPANY SHARE ANALYSIS 378
16.3.4 PRODUCT PORTFOLIO 378
16.3.5 RECENT DEVELOPMENTS 378
16.4 BD 379
16.4.1 COMPANY SNAPSHOT 379
16.4.2 REVENUE ANALYSIS 379
16.4.3 COMPANY SHARE ANALYSIS 380
16.4.4 PRODUCT PORTFOLIO 380
16.4.5 RECENT DEVELOPMENTS 380
16.5 F.HOFFMANN-LA-ROCHE LTD. 381
16.5.1 COMPANY SNAPSHOT 381
16.5.2 REVENUE ANALYSIS 381
16.5.3 COMPANY SHARE ANALYSIS 382
16.5.4 PRODUCT PORTFOLIO 382
16.5.5 RECENT DEVELOPMENTS 383
16.6 ABBOTT 384
16.6.1 COMPANY SNAPSHOT 384
16.6.2 REVENUE ANALYSIS 384
16.6.3 PRODUCT PORTFOLIO 385
16.6.4 RECENT DEVELOPMENTS 385
16.7 BINX HEALTH, INC. 386
16.7.1 COMPANY SNAPSHOT 386
16.7.2 PRODUCT PORTFOLIO 386
16.7.3 RECENT DEVELOPMENT 386
16.8 BIOMERIEUX SA 387
16.8.1 COMPANY SNAPSHOT 387
16.8.2 REVENUE ANALYSIS 387
16.8.3 PRODUCT PORTFOLIO 388
16.8.4 RECENT DEVELOPMENT 388
16.9 BIO-RAD LABORATORIES, INC. 389
16.9.1 COMPANY SNAPSHOT 389
16.9.2 REVENUE ANALYSIS 389
16.9.3 PRODUCT PORTFOLIO 390
16.9.4 RECENT DEVELOPMENTS 390
16.10 CO-DIAGNOSTICS, INC. 392
16.10.1 COMPANY SNAPSHOT 392
16.10.2 REVENUE ANALYSIS 392
16.10.3 PRODUCT PORTFOLIO 393
16.10.4 RECENT DEVELOPMENTS 393
16.11 GENMARK DIAGNOSTICS, INC 394
16.11.1 COMPANY SNAPSHOT 394
16.11.2 REVENUE ANALYSIS 394
16.11.3 PRODUCT PORTFOLIO 395
16.11.4 RECENT DEVELOPMENT 395
16.12 GRIFOLS, S.A. 396
16.12.1 COMPANY SNAPSHOT 396
16.12.2 REVENUE ANALYSIS 396
16.12.3 PRODUCT PORTFOLIO 397
16.12.4 RECENT DEVELOPMENT 397
16.13 LUCIRA HEALTH INC. 398
16.13.1 COMPANY SNAPSHOT 398
16.13.2 PRODUCT PORTFOLIO 398
16.13.3 RECENT DEVELOPMENTS 398
16.14 MERIDIAN BIOSCIENCE 399
16.14.1 COMPANY SNAPSHOT 399
16.14.2 REVENUE ANALYSIS 399
16.14.3 PRODUCT PORTFOLIO 400
16.14.4 RECENT DEVELOPMENTS 400
16.15 OXFORD NANOPORE TECHNOLOGIES 401
16.15.1 COMPANY SNAPSHOT 401
16.15.2 PRODUCT PORTFOLIO 401
16.15.3 RECENT DEVELOPMENT 401
16.16 PERKIN ELMER INC. 402
16.16.1 COMPANY SNAPSHOT 402
16.16.2 REVENUE ANALYSIS 402
16.16.3 PRODUCT PORTFOLIO 403
16.16.4 RECENT DEVELOPMENT 403
16.17 QIAGEN 404
16.17.1 COMPANY SNAPSHOT 404
16.17.2 REVENUE ANALYSIS 404
16.17.3 PRODUCT PORTFOLIO 405
16.17.4 RECENT DEVELOPMENTS 405
16.18 QUANTUMDX GROUP LTD. 407
16.18.1 COMPANY SNAPSHOT 407
16.18.2 PRODUCT PORTFOLIO 407
16.18.3 RECENT DEVELOPMENTS 407
16.19 QUIDEL CORPORATION 409
16.19.1 COMPANY SNAPSHOT 409
16.19.2 REVENUE ANALYSIS 409
16.19.3 PRODUCT PORTFOLIO 410
16.19.4 RECENT DEVELOPMENT 410
16.20 RANDOX LABORATORIES LTD. 411
16.20.1 COMPANY SNAPSHOT 411
16.20.2 PRODUCT PORTFOLIO 411
16.20.3 RECENT DEVELOPMENTS 411
16.21 SD BIOSENSOR, INC. 413
16.21.1 COMPANY SNAPSHOT 413
16.21.2 PRODUCT PORTFOLIO 413
16.21.3 RECENT DEVELOPMENT 413
16.22 SEEGENE INC, 414
16.22.1 COMPANY SNAPSHOT 414
16.22.2 REVENUE ANALYSIS 414
16.22.3 PRODUCT PORTFOLIO 415
16.22.4 RECENT DEVELOPMENT 415
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 416
16.23.1 COMPANY SNAPSHOT 416
16.23.2 PRODUCT PORTFOLIO 416
16.23.3 RECENT DEVELOPMENT 416
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 418
16.24.1 COMPANY SNAPSHOT 418
16.24.2 REVENUE ANALYSIS 418
16.24.3 PRODUCT PORTFOLIO 419
16.24.4 RECENT DEVELOPMENT 419
16.25 WONDFO 420
16.25.1 COMPANY SNAPSHOT 420
16.25.2 PRODUCT PORTFOLIO 420
16.25.3 RECENT DEVELOPMENT 420
17 QUESTIONNAIRE 421
18 RELATED REPORTS 424
Segmentation
Short Description
Global Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Region, (North America, Global, South-Asia, South East Asia, Middle East, and Africa), Industry Trends and Forecast to 2028
Market Definition
Point of Care Testing (POCT) is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30x30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through nucleic acid amplification techniques (NAAT) technology. NAAT allows the identification of pathogenic organisms by detecting their DNA or RNA.
In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propel the growth of the market.
Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization.
Market Segmentation
Global molecular point of care testing (using NAAT) market is categorized into five notable segments which are based on product, indication, end user, mode of testing, and distribution channel.
On the basis of product, the global molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents
On the basis of indication, the global molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others
On the basis of end user, the global molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others
On the basis of mode of testing, the global molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing
On the basis of distribution channel, the global molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, and online sales
Market Players
Some of the key market players for the global molecular point of care testing (using NAAT) market are listed below:
Danaher
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
Sekisui Diagnostics
QuantuMDx Group Ltd.
Lucira Health Inc.
binx health, inc.
Sysmex (A Subsidiary of Sysmex Corporation)
Co-Diagnostics, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.